Feruloyl coenzyme A 6 '-hydroxylase surface mutant and application thereof
By performing amino acid mutation of feruloyl Coenzyme A 6'-hydroxylase and constructing recombinant plasmids, the biosynthesis efficiency and yield of coumarin compounds are improved, and the biosynthesis yield of coumarin compounds in the prior art is solved The problem of low efficiency and economical biosynthesis is achieved.
Patent Information
- Application Number
- CN202410968134.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-18
AI Technical Summary
In the prior art, the biosynthesis yield of coumarin compounds is low, especially the biosynthesis efficiency of chinipin and scopolamine is not high, which limits the efficiency and cost of their industrial production.
By mutation of the amino acid sequence of feruloyl Coenzyme A 6’-hydroxylase, a highly active surface mutant was obtained, and the biosynthesis efficiency and yield of coumarin compounds were improved.
The production of coumarin compounds such as scopolin, quinpi, quinpi, quinpi, and quinpi, has been significantly improved without affecting bacterial growth. Production of viral compounds.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedical engineering, and specifically relates to a surface mutant of feruloyl-CoA 6'-hydroxylase and application thereof. Background Art
[0002] Coumarin (1,2-benzopyrone) is an important secondary metabolite, which exists in large quantities in various organisms such as plants, fungi and bacteria. Due to its special structure, coumarin derivatives have been found to have a variety of biological activities, including antiviral, anticancer, antihypertensive, antihyperuricemic, antibacterial, anti-inflammatory and anticoagulant. In addition, coumarin also has unique fluorescence properties. Therefore, coumarin compounds are widely used in fragrances and cosmetics, dyes, antioxidant agents, etc., and are a research hotspot in the chemical and pharmaceutical industries at home and abroad.
[0003] In the metabolism of plants and bacteria, carbon sources can be converted into L-tyrosine through the shikimic acid metabolic pathway, L-tyrosine is converted into p-coumaric acid (p-CA) by tyrosine ammonia lyase (TAL), p-coumaric acid is converted into caffeic acid (CA) by flavin reductase (Fre) and p-hydroxyphenylacetic acid-3-hydroxylase (HpaBC), and caffeic acid is converted into ferulic acid by caffeic acid methoxytransferase (COMT). Using precursors such as caffeic acid and ferulic acid as raw materials, it combines with p-coumaryl-CoA ligase (4CL) and feruloyl-CoA 6'-hydroxylase (F6'H) to carry out the biosynthesis of scopolamine and scopolamine. The above two coumarins can be synthesized into various high-value-added coumarin compounds through a series of derivatization reactions, such as hydroxylation, glycosylation and isopentenylation. Therefore, scopolamine and scopolamine are important platform compounds in the synthesis of coumarin compounds and are the key to the synthesis of other coumarin compounds. For example, BASF et al. disclosed coumarin synthesis and its use (COUMARIN SYNTHESIS AND USESTHEREOF) in WO2023156270A1 filed on February 8, 2023. The patent application discloses the biosynthetic pathways of coumarin compounds such as scopolamine, scopolamine, and scopolamine.
[0004] Although the prior art discloses that esculetin and scopolamine are important biosynthetic pathways for the synthesis of coumarin compounds, these platform compounds still have problems such as low biosynthetic yield. Summary of the invention
[0005] According to research, feruloyl-CoA 6'-hydroxylase (F6'H) is the rate-limiting enzyme for the biosynthesis of coumarin compounds. Therefore, one of the main purposes of the present invention is to provide a surface mutant of feruloyl-CoA 6'-hydroxylase, which can improve the enzyme activity and is conducive to effectively increasing the yield of biosynthetic coumarin compounds without affecting the growth of bacteria.
[0006] The second main purpose of the present invention is to utilize the above-mentioned feruloyl-CoA 6'-hydroxylase surface mutant in the biosynthesis of coumarin compounds, such as aesculetin, aesculetin, scopolamine, aesculetin, aesculetin and scopolamine, which is conducive to the efficient biosynthesis of coumarin compounds, especially to the efficient de novo synthesis of coumarin compounds with a simple carbon source as the source. Wherein, the "simple carbon source" in the present invention refers to a monosaccharide, a disaccharide or any combination thereof.
[0007] Specifically, the technical solution provided by the present invention is as follows:
[0008] A surface mutant of feruloyl-CoA 6'-hydroxylase (F6'H1) is mainly obtained by amino acid mutation of the amino acid sequence shown in SEQ ID NO.1, including at least one of the following amino acid mutations: D102E, E163K, E190K, L196F, and K199N. Among them, the mutant D102E represents that the aspartic acid at position 102 is mutated to glutamic acid, the mutant E163K represents that the glutamic acid at position 163 is mutated to lysine, the mutant E190K represents that the glutamic acid at position 190 is mutated to lysine, the mutant L196F represents that the leucine at position 196 is mutated to phenylalanine, and the mutant K199N represents that the lysine at position 199 is mutated to asparagine.
[0009] The amino acid mutation may be a single mutation, a double mutation, a triple mutation, a quadruple mutation or a pentamutation. The amino acid mutation is preferably D102E-E190K or D102E-E163K-E190K. Wherein, the D102E-E190K mutation is a double mutation in which the two sites D102E and E190K mutate simultaneously, which represents that the aspartic acid at position 102 mutates to glutamic acid, and the glutamic acid at position 190 mutates to lysine. The D102E-E163K-E190K mutation is a triple mutation in which the three sites D102E, E163K and E190K mutate simultaneously, which represents that the aspartic acid at position 102 mutates to glutamic acid, and the glutamic acid at position 163 mutates to lysine, and the glutamic acid at position 190 mutates to lysine.
[0010] The feruloyl-CoA 6'-hydroxylase (F6'H1) is derived from Arabidopsis thaliana.
[0011] The method for obtaining the above-mentioned feruloyl-CoA 6'-hydroxylase surface mutants specifically includes: designing a feruloyl-CoA 6'-hydroxylase gene mutant library by an error-prone PCR method; obtaining dominant mutants by an established high-throughput screening method; and selecting the feruloyl-CoA 6'-hydroxylase surface mutant with the best effect by combining protein purification and in vitro enzyme activity experiments.
[0012] A gene encoding the above-mentioned feruloyl-CoA 6'-hydroxylase (F6'H1) mutant.
[0013] A recombinant plasmid, the recombinant plasmid is connected with the above gene. Preferably, the plasmid includes but is not limited to pETDuet-1, pZE12-luc, pCS27 or pSA74.
[0014] A use of the above-mentioned surface mutant of feruloyl-CoA 6'-hydroxylase in the biosynthesis of coumarin compounds, wherein the coumarin compounds can be aesculetin, aesculetin, chicory glycoside, scopoletin, aesculetin, aesculetin and scopolamine.
[0015] An engineered bacterium for synthesizing coumarin compounds, comprising a host bacterium and the above-mentioned recombinant plasmid transformed into the host bacterium. Wherein, the host bacterium is a non-plant cell. Preferably, the host bacterium is an original or modified bacterium, an original or modified fungus; for example, an original or modified Escherichia coli, Bacillus subtilis, Corynebacterium glutamicum, Saccharomyces cerevisiae or Pichia pastoris, etc. More preferably, the host bacterium can be Escherichia coli BW25113; further more preferably, the Escherichia coli is BW25113ΔpykA / F::aroG fbr ::tyrA fbr ; In this way, pyruvate kinase was knocked out and the feedback inhibition of 2-dehydro-3-deoxyheptanoic acid phosphoenolase AroG was relieved. fbr and chorismate mutase / prephenate dehydrogenase TyrA fbr , which can increase the yield of tyrosine synthesized by the shikimic acid pathway, thereby enhancing the upstream pathway to increase the yield of coumarin compounds synthesized from scratch by engineered bacteria that synthesize coumarin compounds.
[0016] Based on the above engineering bacteria for synthesizing coumarin compounds, the recombinant plasmid is also connected with genes encoding tyrosine ammonia lyase (TAL), flavin reductase (Fre), p-hydroxyphenylacetic acid-3-hydroxylase (HpaBC), caffeic acid methoxytransferase (COMT), p-coumaryl-CoA ligase (4CL) and coumarin synthase (COSY). In this way, the engineering bacteria is a scopolamine synthetic engineering bacteria, which can achieve efficient synthesis of scopolamine; in particular, it can achieve efficient synthesis of scopolamine from scratch with a simple carbon source as the source. In addition, the scopolamine synthetic engineering bacteria is a simple coumarin synthetic engineering bacteria, which can be used as a starting bacteria to construct scopolamine, fraxin, fraxinin and other coumarin compound synthetic engineering bacteria.
[0017] Based on the scopolamine synthesis engineered bacteria, the recombinant plasmid is also connected with a gene encoding scopolamine-glycosyltransferase. In this way, the engineered bacteria is a scopolamine synthesis engineered bacteria, which can achieve efficient synthesis of scopolamine; in particular, it can achieve efficient synthesis of scopolamine from scratch using a simple carbon source as the source.
[0018] Based on the scopolamine synthetic engineered bacteria, the recombinant plasmid is also connected with a gene encoding scopolamine-8-hydroxylase (S8H), so that the engineered bacteria is a quercetin synthetic engineered bacteria, which can achieve efficient synthesis of quercetin; in particular, it can achieve efficient synthesis of quercetin from scratch with a simple carbon source as the source. In addition, the quercetin synthetic engineered bacteria can also be used as the starting bacteria to construct an engineered bacteria for the synthesis of coumarin compounds such as quercetin.
[0019] Based on the above-mentioned quercetin synthesis engineered bacteria, the recombinant plasmid is also connected with a gene encoding quercetin-8-O-glycosyltransferase, so that the engineered bacteria is a quercetin synthesis engineered bacteria, which can achieve efficient synthesis of quercetin; in particular, it can achieve efficient synthesis of quercetin from scratch using a simple carbon source as the source.
[0020] Based on the above engineering bacteria for synthesizing coumarin compounds, the recombinant plasmid is also connected with genes encoding tyrosine ammonia lyase (TAL), flavin reductase (Fre), p-hydroxyphenylacetic acid-3-hydroxylase (HpaBC), p-coumaroyl-CoA ligase (4CL) and coumarin synthase (COSY). In this way, the engineering bacteria is a quatidine synthesis engineering bacteria, which can achieve efficient synthesis of quatidine; in particular, it can achieve efficient synthesis of quatidine from scratch with a simple carbon source as the source. In addition, the quatidine synthesis engineering bacteria is a simple coumarin synthesis engineering bacteria, which can be used as a starting bacteria to construct a synthesis engineering bacteria for coumarin compounds such as chicory glycoside and quatidine.
[0021] Based on the aesculetin synthesis engineered bacteria, the recombinant plasmid is also connected with a gene encoding scopoletin-7-O-glycosyltransferase (GT). In this way, the engineered bacteria is a chicorin synthesis engineered bacteria, which can achieve efficient synthesis of chicorin; in particular, it can achieve efficient synthesis of chicorin from scratch using a simple carbon source as the source.
[0022] Based on the aesculetin synthesis engineered bacteria, the recombinant plasmid is also connected with a gene encoding aesculetin-6-O-glycosyltransferase (UGT). In this way, the engineered bacteria is an aesculetin synthesis engineered bacteria, which can achieve efficient synthesis of aesculetin; in particular, it can achieve efficient de novo synthesis of aesculetin with a simple carbon source as the source, and its de novo synthesis yield can reach 254.8 mg / L.
[0023] In the present invention, the tyrosine ammonia lyase (TAL) is preferably derived from Rhodobacter sphaeroides, Rhodobacter glutinis, Streptomyces albus, Rhodobacter capsulatus or Micromonospora echinofusca, etc.; the p-coumaroyl-CoA ligase (4CL) is preferably derived from Arabidopsis thaliana or Petroselinum crispum, etc. The flavin reductase (Fre) is derived from Escherichia coli, the p-hydroxyphenylacetic acid-3-hydroxylase (HpaBC) is derived from Klebsiella pneumonia, and the caffeic acid methoxytransferase (COMT) is derived from Arabidopsis thaliana. The coumarin synthase (COSY) is derived from Arabidopsis thaliana, Solanum tuberosum or Glycine max, etc. The scopoletin-8-hydroxylase (S8H) is derived from Arabidopsis thaliana. The scopoletin-8-O-glycosyltransferase UGT71E is derived from Arabidopsis thaliana, and can be UGT71E1, UGT71E2, or UGT71E3. The scopoletin-glycosyltransferase GT is derived from Nicotiana tabacum or Arabidopsis thaliana, and can be a 7-O-glycosyltransferase or an 8-O-glycosyltransferase, such as TOGT1, TOGT2, UGT71E1, UGT71E2, or UGT71E3. The scopoletin-6-O-glycosyltransferase UGT is derived from Dipteronia sinensis, such as UGT92G7, UGT84A62, and the like.
[0024] A method for biosynthesis of coumarin compounds, comprising: inoculating the engineered bacteria for synthesizing coumarin compounds into a fermentation medium at an inoculation volume of 1% to 10% for fermentation culture to obtain coumarin compounds. The inoculation volume is preferably 2% to 5%; the fermentation temperature is preferably 30°C to 40°C for fermentation treatment; the fermentation medium preferably comprises: 0.5 to 1.5 g / L FeSO4, 1 to 5 g / L MOPS, 5 to 20 g / L carbon source, 1 to 5 g / L yeast powder, 5 to 8 g / L Na2HPO4, 0.3 to 2 g / L NaCl, 2.3 to 4.0 g / L KH2PO4 and 1 to 5 g / L NH4Cl.
[0025] The carbon source in the fermentation medium is a monosaccharide, a disaccharide or any combination thereof. Preferably, the carbon source in the fermentation medium is one or any combination of glycerol, glucose, sucrose, fructose and xylose. In the fermentation culture process, 0.25-1 mM of the inducer IPTG is added.
[0026] Furthermore, the above-mentioned synthesis method also includes the step of first adding an intermediate compound to the fermentation medium and then fermenting and culturing the engineered bacteria; wherein the intermediate compound is an intermediate on the path of synthesizing the target compound, preferably at least one of tyrosine, p-coumaric acid, caffeic acid, ferulic acid, scopoletin, quercetin and quercetin.
[0027] Therefore, the above-mentioned feruloyl-Coenzyme A 6'-hydroxylase surface mutant provided by the present invention is obtained by mutating the wild-type feruloyl-Coenzyme A 6'-hydroxylase through random mutation technology, and can improve the activity of feruloyl-Coenzyme A 6'-hydroxylase. According to experiments, the enzyme activity of the feruloyl-Coenzyme A 6'-hydroxylase mutant is increased by more than 1.7, and can even be increased by 8.4 times; compared with the engineered bacteria constructed using the wild-type feruloyl-Coenzyme A 6'-hydroxylase, the engineered bacteria constructed using the feruloyl-Coenzyme A 6'-hydroxylase surface mutant can increase the yield of scopoletin by about 8.4 times and the yield of esculetin by about 5.1 times.
[0028] Furthermore, the present invention utilizes the above-mentioned feruloyl-CoA 6'-hydroxylase surface mutant to realize for the first time the efficient biosynthesis of scopoletin, quercetin, quercetin, scopolamine, quercetin, quercetin A, and chicorylin from scratch using a simple carbon source as the source, with the yields being 49.3 mg / L, 45.8 mg / L, 101.2 mg / L, 79.8 mg / L, 78.6 mg / L, 254.8 mg / L, and 73.9 mg / L, respectively.
[0029] Furthermore, the production of coumarin compounds using the engineered bacteria containing the gene encoding the surface mutant of feruloyl-CoA 6'-hydroxylase provided by the present invention has the advantages of high yield and a wide variety of types, is conducive to industrialized scale-up production, reduces production costs, and provides an important basis for the industrial production of coumarin compounds. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 It is a schematic diagram of the production pathway of aesculetin, aesculetin, chicory glycoside, scopoletin, aesculetin, aesculetin and scopoletin using genetically engineered bacteria;
[0031] Figure 2 This is a workflow diagram of a high-throughput screening method established using the fluorescence properties of coumarin;
[0032] Figure 3 This is a diagram of the fermentation result of synthesizing scopoletin using the scopoletin synthesis engineering bacteria BW20 in Example 3 of the present invention;
[0033] Figure 4 This is a diagram of the fermentation result of synthesizing quercetin by using the quercetin synthesis engineering bacteria BW30 and adding ferulic acid in vitro in Example 4 of the present invention;
[0034] Figure 5 This is a diagram showing the fermentation result of synthesizing fraxinoin from scratch using the fraxinoin synthetic engineering bacteria BW30 in Example 4 of the present invention;
[0035] Figure 6 This is a diagram showing the fermentation results of synthesizing fraxinoside using the fraxinoside synthesis engineering bacteria BW30 in Example 5 of the present invention, under the conditions of different fraxinoside-8-O-glycosyltransferases, by adding ferulic acid in vitro;
[0036] Figure 7 This is a diagram showing the fermentation results of synthesizing fraxinoside using the fraxinoside synthesis engineering bacteria BW41 in Example 5 of the present invention;
[0037] Figure 8 This is a diagram of the fermentation results of synthesizing scopoletin by using the scopoletin synthesis engineering bacteria BW5 in Example 6 of the present invention, under different scopoletin-glycosyltransferase conditions, by adding ferulic acid in vitro;
[0038] Fig. 9 This is a fermentation result diagram of synthesizing scopoletin from scratch using the scopoletin synthesis mutant engineering bacteria BW50 in Example 6 of the present invention;
[0039] Fig.10 This is a diagram showing the fermentation result of synthesizing aesculetin using the aesculetin synthesis engineering bacteria BW60 in Example 7 of the present invention;
[0040] Fig.11 This is a diagram of the fermentation results of synthesizing aesculin by adding caffeic acid in vitro under different aesculin-6-O-glycosyltransferase conditions using the aesculin synthesis engineering bacteria BW7 in Example 8 of the present invention;
[0041] Fig.12 This is a diagram of the fermentation result of synthesizing aesculin from scratch using the aesculin synthesis mutant engineered bacteria BW71 according to Example 8 of the present invention;
[0042] Fig.13 This is a diagram showing the fermentation results of synthesizing chicory glycoside by adding caffeic acid in vitro under different scopoletin-glycosyltransferase conditions using chicory glycoside synthesis engineering bacteria BW8 in Example 9 of the present invention;
[0043] Fig.14This is a diagram of the fermentation results of synthesizing chicorylin from scratch using the chicorylin synthesis mutant engineered bacteria BW81 according to Example 9 of the present invention.
[0044] In the sequence list:
[0045] SEQ ID NO.1 is the amino acid sequence of wild-type feruloyl-CoA 6'-hydroxylase F6'H;
[0046] SEQ ID NO.2 is the nucleotide sequence shown by primer F6H1-F;
[0047] SEQ ID NO.3 is the nucleotide sequence shown by primer F6H1-R;
[0048] SEQ ID NO.4 is the nucleotide sequence shown by primer D102E-F;
[0049] SEQ ID NO.5 is the nucleotide sequence shown by primer E102E-R;
[0050] SEQ ID NO.6 is the nucleotide sequence shown by primer E163K-F;
[0051] SEQ ID NO.7 is the nucleotide sequence shown by primer E163K-R;
[0052] SEQ ID NO.8 is the nucleotide sequence shown by primer E190K-F;
[0053] SEQ ID NO.9 is the nucleotide sequence shown by primer E190K-R;
[0054] SEQ ID NO.10 is the nucleotide sequence shown by primer L196F-F;
[0055] SEQ ID NO.11 is the nucleotide sequence shown by primer L196F-R;
[0056] SEQ ID NO.12 is the nucleotide sequence shown by primer K199N-F;
[0057] SEQ ID NO.13 is the nucleotide sequence shown by primer K199N-R. DETAILED DESCRIPTION
[0058] The technical solution of the present invention is further described in detail below through specific implementation methods. In the present invention, there is no special requirement for the type of expression plasmid. It can be considered that the construction method for expressing the target gene in Escherichia coli can adopt various methods commonly used in the art, such as connecting the target gene to the vector after enzyme digestion, replacing the promoter, knocking out the gene method, gene mutation method, etc., which will not be repeated hereafter.
[0059] 1) Enzymes used in the examples
[0060] The various enzymes involved in the present invention are all derived from commonly used substances, and the sources of the enzymes are not limited to those listed in the present invention. As long as the similarity with the enzymes listed in the present invention is within 80%, they are within the protection scope of the present invention. In the following examples and comparative examples, in addition to the key enzymes shown in Table 1, other enzymes such as various enzymes used in the pathway for synthesizing shikimic acid from carbon sources are also existing commonly used enzymes.
[0061] Table 1 Enzymes used in various examples and comparative examples
[0062] Enzymes source NCBI Gene database accession number TAL Red yeast Rhodotorula NP_001106047.1 4CL Arabidopsis thaliana NP_175579.1 Fre Escherichia coli NP_418286.1 HpaB Klebsiella pneumonia NP_252781.1 COMT Arabidopsis thaliana NP_001106047.1 F6'H1 Arabidopsis thaliana NP_187970.1 COSY Arabidopsis thaliana AT1G28680.1 COSY PotatoSolanum tuberosum NC_003070.9 COSY Glycine max DQ280500.1 S8H Arabidopsis thaliana AT3G12900.1 TOGT1 Nicotiana tabacum AF346431 TOGT2 Nicotiana tabacum AF346432 UGT71E1 Arabidopsis thaliana NP_566938.1 UGT71E2 Arabidopsis thaliana NP_201470.1 UGT71E3 Arabidopsis thaliana NP_198003.1 UGT92G7 Dipteronia sinensis KAK3204518.1 UGT84A62 Dipteronia sinensis KAK3217807.1
[0063] 2) E. coli related test steps
[0064] E. coli transformation, plasmid extraction, DNA gel recovery, DNA fragment ligation, nickel column protein purification, etc. were all performed according to the corresponding kit instructions or conventional steps.
[0065] The transformed E. coli clones were identified by plasmid PCR. A single colony was picked from the plate and inoculated into a test tube. After plasmid extraction, 2× Taq Plus Master Mix II DNA polymerase was used to perform plasmid PCR verification, and the cloned segment was identified by DNA sequencing. The E. coli colony PCR amplification system and reaction conditions are shown in Table 2.
[0066] Table 2 Escherichia coli colony PCR amplification system and reaction conditions
[0067]
[0068] 3) Preparation and transformation of E. coli competent cells
[0069] Streak the host strain stored in the glycerol tube on a non-resistant LB plate and place it in a 37°C constant temperature incubator overnight. Inoculate the single colony grown on the plate into 4 mL LB non-resistant liquid medium and culture it in a constant temperature shaker at 37°C, 220 rpm overnight. Transfer the seed liquid strain in the test tube to 50 mL LB liquid medium and culture it at 37°C, 220 rpm for 1.5-2 hours until the OD 600Reach about 0.4-0.6. Pour the bacterial solution into a sterilized 50mL centrifuge tube, centrifuge at 5000rpm for 5min at 4℃, remove the supernatant and collect the bacteria. Add 20mL of sterilized 10% glycerol to the centrifuge tube, wash away the residual culture medium, centrifuge at 5000rpm for 5min at 4℃, and repeat this operation twice. Add 500μL of sterilized 10% glycerol to resuspend the bacteria, divide into 100μL per tube for transformation. Take a clean 1mm electroporation cup, place it on ice for later use, add the plasmid to be transformed to the competent state, gently blow and mix, and add it to the electroporation cup; turn on the electroporator, set the transformation mode, push the electroporation cup with the mixed solution between the two electrodes, and perform electric shock. After the electroporation, add 600 μL of LB sterile medium to the electroporation cup, gently blow and mix to fully mix the bacterial solution and the medium, then transfer to a 1.5 mL centrifuge tube and place in a 37°C constant temperature incubator to recover for 45-60 minutes. Take 100 μL of the recombinant strain and evenly spread it on a selective solid medium with the corresponding antibiotics, and place it in a 37°C constant temperature incubator overnight to culture a single colony.
[0070] 4) Culture medium used in the embodiment
[0071] LB medium: yeast powder 5g / L, peptone 10g / L, sodium chloride 10g / L;
[0072] The fermentation medium used was: 2 g / L MOPS, 20 g / L glycerol, 5 g / L yeast powder, 6.78 g / L Na2HPO4, 0.5 g / L NaCl, 3 g / L KH2PO4 and 1 g / L NH4Cl;
[0073] 5) Plasmids and strains used in the examples
[0074] In the following examples, E. coli strains BW25113, BL21 (DE3) and trans5α are all commonly used E. coli strains, all of which are commercially available, wherein trans5α is used for vector construction, BL21 (DE3) is used for protein expression, and BW25113 is used as the initial host strain for constructing expression plasmids. The plasmids and strains used in each example are shown in Table 3.
[0075] Table 3 Plasmids mainly used in each embodiment and comparative example
[0076]
[0077]
[0078] Among them, the recombinant Escherichia coli BW1 in Table 3: BW25113ΔpykA / F::AroG fbr ::TyrA fbrThis was mainly achieved by knocking out pyruvate kinase pykA / F and overexpressing the endogenous key enzyme AroG in the shikimate pathway. fbr 、TyrA fbr To enhance the supply of shikimic acid pathway, increase the production of tyrosine, and help increase the production of coumarin compounds. The construction method of strain BW1 mainly includes: firstly using the RED knockout method to knock out the gene pykA / F in the chromosome of Escherichia coli BW25113 to obtain Escherichia coli BW25113ΔpykA / F; then using the CRISPR-Cas9 recombination method to knock out aroG fbr 、TyrA fbr Integrated into the genome of Escherichia coli BW25113ΔpykA / F.
[0079] 6) Detection conditions of HPLC analysis adopted in the embodiment
[0080] a) In the embodiment, the HPLC analysis method was used to detect the standard products and fermentation products of aesculetin, aesculetin, chicory glycoside, scopoletin, aesculetin, aesculetin and scopoletin under the following conditions:
[0081] Chromatographic column: Separation column: Diamonsil C18, ID 5 μm, 250 × 4.6 mm;
[0082] Mobile phase: A is methanol, B is 2‰ trifluoroacetic acid aqueous solution, column temperature is 40°C, flow rate is 1.0mL / min, and detection wavelength is 345nm. The gradient elution program is shown in Table 4 below:
[0083] Table 4 Gradient elution program
[0084] Time (min) Mobile phase A% Mobile phase B% 0 5 95 10 35 65 20 85 15 25 5 95
[0085] In the following examples, feruloyl-CoA 6'-hydroxylase F6'H1 gene (NP_187970.1) from Arabidopsis thaliana was used to perform evolutionary modification on feruloyl-CoA 6'-hydroxylase, thereby obtaining a feruloyl-CoA 6'-hydroxylase mutant with higher catalytic activity.
[0086] See also Figure 1The original carbon source is converted into tyrosine through the shikimate pathway, tyrosine is converted into p-coumaric acid by tyrosine ammonia lyase TAL, p-coumaric acid is converted into caffeic acid (CA) under the catalysis of flavin reductase Fre and p-hydroxyphenylacetic acid-3-hydroxylase HpaBC, caffeic acid is catalyzed by p-coumaryl-CoA ligase 4CL and feruloyl-CoA 6'-hydroxylase F6'H to generate 6-hydroxycaffeoyl-CoA, and then catalyzed by coumarin synthase COSY or spontaneously isomerized to generate quercetin; quercetin is converted into chicoryl by scopoletin-glycosyltransferase (GT); quercetin can also be converted into quercetin A by catalysis of quercetin-6-O-glycosyltransferase UGT.
[0087] Caffeic acid can also be converted into ferulic acid (FA) under the catalysis of caffeic acid methoxytransferase COMT, and ferulic acid is catalyzed by p-coumaroyl-CoA ligase 4CL and feruloyl-CoA 6'-hydroxylase F6'H to generate hydroxyferuloyl-CoA, and then catalyzed by coumarin synthase COSY or spontaneous isomerization to generate scopolamine; scopolamine is converted into quercetin under the catalysis of scopolamine-8-hydroxylase (S8H); quercetin is converted into quercetin by catalysis of quercetin-8-O-glycosyltransferase (UGT71E); scopolamine can also be converted into scopolamine by scopolamine-glycosyltransferase (GT).
[0088] Therefore, the following examples introduce the obtained feruloyl-CoA 6'-hydroxylase surface mutants into Escherichia coli, further improving the production of scopoletin and aesculetin, providing a reference for the microbial synthesis of coumarin compounds.
[0089] Example 1: Establishment of a fluorescence-based high-throughput screening method for screening dominant mutants of feruloyl-CoA 6'-hydroxylase F6'H1
[0090] This example is based on the wild-type Arabidopsis thaliana-derived feruloyl-CoA 6'-hydroxylase F6'H1 gene, and the amino acid sequence shown in SEQ ID NO.1 is mutated to obtain a feruloyl-CoA 6'-hydroxylase F6'H1 mutant with higher catalytic activity and stability. Figure 2 The design, construction and screening methods of the feruloyl-CoA 6'-hydroxylase F6'H1 mutant are as follows:
[0091] (1) Construction of a surface mutant library of feruloyl-CoA 6'-hydroxylase F6'H1
[0092] Plasmid pZE12-F6'H1-4CL was used as a template for subsequent PCR, wherein the plasmid was mainly obtained by connecting the genes encoding F6'H1 and 4CL to the vector plasmid pZE12-luc.
[0093] Step 1, design primers using the target sequence as a template;
[0094] Step 2, error-prone PCR using a random mutagenesis kit;
[0095] Step 3, gel recovery of PCR products and double enzyme digestion with the template vector;
[0096] Step 4, T4 ligase connects the mutant library gene with sticky ends and the vector;
[0097] Step 5, transformation, introducing the obtained cyclized product into E. coli DH5α competent cells, and transferring to a test tube for further culture;
[0098] Step 6: After plasmid extraction, electrotransform into Escherichia coli BW25113 to obtain recombinant Escherichia coli.
[0099] (2) Feeding substrate and fluorescence screening
[0100] Step 1, pick a single colony of the recombinant Escherichia coli and inoculate it into a 96-well plate with 0.9 mL of LB medium in each well, and ferment and culture at 1000 rpm and 30°C;
[0101] Step 2: After 12 h, add 0.7 mM ferulic acid and continue fermentation at 1000 rpm and 30°C;
[0102] Step 3: After 36 h, the 96-well plate was taken out and centrifuged at 4000 rpm for 10 min. 200 μL of the supernatant was aspirated into a black ELISA plate and fluorescence was detected at 345 nm / 465 nm.
[0103] Step 4, select bacteria with high fluorescence values for sequencing, and screen to obtain the recombinant plasmid of the pZE-F6'H1*-4CL dominant mutant.
[0104] Finally, the following mutants were screened: D102E, E190K, E163K, L196F and K199N (the mutation sites were located on the surface of the protein), and a mutation library was designed around these four groups of mutation sites.
[0105] The primers used in this example are shown in Table 5 below
[0106] Table 5 Primer sequences used in the construction of feruloyl-CoA 6'-hydroxylase F6'H1 mutant
[0107]
[0108] Table 5 lists the primers for single mutations of all mutation sites. Multiple mutants are obtained by further mutations based on the double mutant D102E-E190K. Specifically, triple mutants are obtained by further mutations based on the double mutant D102E-E190K, and quadruple mutants are obtained by further mutations based on the triple mutant. Therefore, primers for multiple mutants are not repeated.
[0109] Example 2: Screening of surface mutants of feruloyl-CoA 6'-hydroxylase by in vitro enzyme activity assay
[0110] Step 1: The single mutant and multiple mutant genes obtained in Example 1 were constructed on the pETDuet-1 plasmid and transformed into Escherichia coli BL21 (DE3), and induced in 50 mL LB medium at 30° C. for 10 h.
[0111] Step 2, the collected bacteria are subjected to cell disruption, nickel column purification, and ultrafiltration to obtain purified protein.
[0112] Step 3, the protein obtained in step 2 is reacted with the substrate feruloyl-CoA, the cofactor α-ketoglutaric acid and ferrous sulfate in a 100 μL system for 5 min, 20 μL of sodium hydroxide is added to terminate the reaction, and then 20 μL of acetic acid is added to neutralize the solution, the mixture is transferred to a black ELISA plate, and fluorescence is detected at 345 nm / 465 nm.
[0113] Step 4: Import the collected data into Origin 2022, fit the Michaelis equation curve, and calculate K m and k cat The test results are shown in Table 6.
[0114] Table 6 Enzyme activity of feruloyl-CoA 6'-hydroxylase F6'H1 on feruloyl-CoA
[0115] F6'H1 mutation site <![CDATA[k cat / K m (my -1 μM -1 )]]> Increased compared to wild type wild type 1.38 -- D102E / E190K 6.93 5.0 times E163K 5.34 3.9 times L196F 4.23 3.1 times K199N 2.28 1.7 times D102E / E163K / E190K 11.58 8.4 times D102E / L196F / E190K 5.13 3.7 times D102E / E190K / K199N 4.17 3.0 times D102E / E163K / E190K / L196F 3.95 2.7 times D102E / E163K / E190K / K199N 4.03 2.9 times D102E / E163K / E190K / L196F / K199N 3.02 2.2 times
[0116] It can be seen from Table 6 that the enzyme activity of the D102E-E163K-E190K mutant of feruloyl-CoA 6'-hydroxylase F6'H1 is the highest, which is 8.4 times that of the wild-type F6'H1.
[0117] Example 3 Application of Feruloyl-CoA 6'-Hydroxylase F6'H1 Mutant in the Synthesis of Scopoletin
[0118] (1) Scopoletin synthesis engineering bacteria and construction method thereof
[0119] This embodiment provides a scopoletin synthesis engineering strain BW2: BW1 (pZE-F6'H1-COSY, pCS-TAL-FreHpaBC-COMT-4CL), and the construction method of the strain mainly includes the following steps:
[0120] First, tyrosine ammonia lyase TAL, p-coumaryl-CoA ligase 4CL, flavin reductase Fre, p-hydroxyphenylacetic acid-3-hydroxylase HpaBC, caffeic acid methoxytransferase COMT, feruloyl-CoA 6'-hydroxylase F6'H1, and coumarin synthase COSY were selected for PCR amplification to obtain the corresponding gene fragments, and then the fragments and vectors were double-digested with nucleases, and the digested fragments were recovered by gel or column. After that, the target genes were inserted into plasmids pZE12-luc (high copy) and pCS27 (medium copy) to obtain pZE-F6'H1-COSY and pCS-TAL-FreHpaBC-COMT-4CL recombinant plasmids, respectively (Table 3). Among them, the recombinant plasmid pZE-F6'H1-COSY is mainly obtained by connecting the genes encoding F6'H1 and COSY to the vector plasmid pZE12-luc; the recombinant plasmid pCS-TAL-FreHpaBC-COMT-4CL is mainly obtained by connecting the genes encoding TAL, 4CL, FreHpaBC and COMT to the same vector plasmid pCS27.
[0121] The scopoletin synthesis engineering strain BW2:BW1 (pZE-F6'H1-COSY, pCS-TAL-FreHpaBC-COMT-4CL) was prepared by the same method as in "3) Preparation and transformation of Escherichia coli competent cells". In this example, F6'H1 can be a wild type or a mutant.
[0122] (2) De novo synthesis of scopolamine using simple carbon sources
[0123] Pick a single colony to 4 mL and add it to the corresponding resistance LB medium, culture it at 37°C, 220 rpm constant temperature shaker overnight, and then transfer it to 50 mL fermentation medium until the final OD 600 The induction agent IPTG was added, and then the mixture was transferred to a constant temperature shaker at 33°C and 220 rpm for 72 hours. Among them, 1 mL of fermentation sample was taken at 24, 48, and 72 hours, centrifuged at 12000 rpm for 10 minutes, and the upper layer of liquid was filtered through a 0.22 μm filter membrane into a sample injection bottle. The concentration of the intermediate product and the target product was detected by HPLC. The results are shown in Table 7 and Figure 3As shown. Among them, COSY in the scopoletin synthesis engineering bacteria BW2 comes from Arabidopsis thaliana, Solanum tuberosum, and Glycine max, and the corresponding strains are scopoletin synthesis engineering bacteria BW20, BW21, and BW22, respectively. The scopoletin synthesis engineering bacteria BW23 is basically the same as strain BW20, and the main difference is that: F6'H1 in strain BW23 is a mutant F6'H1 D102E-E163K-E190K , namely strain BW23 scopoletin synthesis mutant engineered bacteria, BW1(pZE-F6'H1 D102E-E163K-E190K -COSY, pCS-TAL-FreHpaBC-COMT-4CL); F6'H1 in strain BW20 is wild type, that is, strain BW20 is a wild type scopoletin synthesis engineering bacterium; other enzymes and their sources are the same.
[0124] Table 7 Results of scopoletin synthesis by scopoletin synthesis engineering bacteria fermentation for 72h
[0125] strain BW20 BW21 BW22 BW23 Yield / mg / L 5.9 4.2 3.5 49.3
[0126] From Table 7 and Figure 3 It can be seen that under the same conditions, the scopoletin synthesis engineered strain BW23 derived from COSY Arabidopsis thaliana has the highest yield of scopoletin, and the yield can reach 49.3 mg / L within 72 hours, which is about 8.4 times that of the wild type.
[0127] Example 4 Application of Feruloyl-CoA 6'-Hydroxylase F6'H1 Mutant in the Synthesis of Fraxin
[0128] (1) Engineering bacteria for the synthesis of quercetin and methods for their construction
[0129] This embodiment provides a quercetin synthesis engineering bacterium BW3: BW1 (pZE-F6'H1 D102E-E163K-E190K -COSY-S8H, pCS-TAL-FreHpaBC-COMT-4CL).
[0130] The construction method of the fraxinin synthesis engineering bacteria is basically the same as the construction method of the engineering bacteria provided in Example 3. First, the recombinant plasmid pZE-F6'H1 is constructed. D102E-E163K-E190K -COSY-S8H and pCS-TAL-FreHpaBC-COMT-4CL, among which, the recombinant plasmid pZE-F6'H1 D102E-E163K-E190K -COSY-S8H mainly encodes F6'H1 D102E-E163K-E190KThe genes of COSY, S8H and 113H were connected to the same vector plasmid pZE12-luc to obtain the recombinant plasmid pZE-F6'H1 D102E -E163K-E190K -COSY-S8H and pCS-TAL-FreHpaBC-COMT-4CL were electroporated into competent cells of Escherichia coli BW1 to construct the quercetin synthesis engineering bacteria BW3: BW1 (pZE-F6'H1 D102E-E163K-E190K -COSY-S8H, pCS-TAL-FreHpaBC-COMT-4CL). In this embodiment, COSY is derived from Arabidopsis thaliana, that is, the quercetin synthesis engineering bacteria BW3 in this embodiment is equivalent to the strain BW30: BW23 (pZE-S8H).
[0131] (2) Synthesis of quercetin by adding ferulic acid in vitro
[0132] The above-mentioned quercetin synthetic engineered bacteria BW3 constructed in this example were streaked and cultured on LB plate culture medium with corresponding resistance, and single colonies were picked from the corresponding plates and transferred to 4 mL of liquid LB culture medium with resistance, and cultured at 37°C for 10 hours, and then the bacterial liquid was transferred to 50 mL of fermentation medium, and 100 mg / L of ferulic acid was added to the fermentation medium, and 0.5 mM IPTG was added for induction. After that, samples were taken at 24, 48, and 72 hours, and the concentrations of intermediates and target products were determined by high performance liquid chromatography. The results are as follows: Figure 4 The quercetin synthesis engineering bacteria BW3 in this embodiment is strain BW30: BW20 (pZE-S8H).
[0133] from Figure 4 It can be seen that when ferulic acid is added in vitro, feruloyl-CoA 6'-hydroxylase F6'H1 D102E -E163K-E190K The mutant quercetin-synthesizing engineered bacteria BW30 were fermented for 72 hours, and the yield of quercetin reached 102.2 mg / L.
[0134] (3) De novo synthesis of quercetin using simple carbon sources
[0135] Using a simple carbon source as the source, the de novo synthesis of quercetin was achieved using the quercetin synthesis engineering bacteria BW30. Compared with the synthesis of quercetin by adding ferulic acid in vitro, the main difference is that no additional ferulic acid is added to the fermentation medium used in the de novo synthesis of quercetin, and the other process methods are the same. Among them, the fermentation situation of de novo synthesis of quercetin using the quercetin synthesis engineering bacteria BW30 is shown in the figure. Figure 5 As shown. Among them, Figure 5 It is shown that: using feruloyl-CoA 6'-hydroxylase F6'H1D102E-E163K-E190K The mutant quercetin-synthesizing engineered bacteria BW30 were fermented for 72 hours, and the de novo synthesized quercetin yield could reach 45.8 mg / L.
[0136] Example 5 Application of Feruloyl-CoA 6'-Hydroxylase F6'H1 Mutant in the Synthesis of Fraxinoside
[0137] (1) Engineering bacteria for the synthesis of quercetin and methods for their construction
[0138] This embodiment provides a quercetin synthesis engineering bacterium BW4: BW3 (pZE-UGT71E), which is equivalent to BW1 (pZE-F6'H1 D102E-E163K-E190K -COSY-UGT71E-S8H, pCS-TAL-FreHpaBC-COMT-4CL).
[0139] The construction method of the engineering bacteria for the synthesis of fraxinoside is basically the same as the construction method of the engineering bacteria provided in Example 3. First, the recombinant plasmid pZE-F6'H1 is constructed. D102E-E163K-E190K -COSY-UGT71E-S8H and pCS-TAL-FreHpaBC-COMT-4CL, among which, the recombinant plasmid pZE-F6'H1 D102E-E163K-E190K -COSY-UGT71E-S8H mainly converts the code F6'H1 D102E-E163K-E190K , COSY, UGT71E and S8H genes were connected to the same vector plasmid pZE12-luc to obtain; then the recombinant plasmid pZE-F6'H1 D102E-E163K-E190K -COSY-UGT71E-S8H and pCS-TAL-FreHpaBC-COMT-4CL were electroporated into competent cells of Escherichia coli BW1 to construct the quercetin synthesis engineering bacteria BW4: BW1 (pZE-F6'H1 D102E-E163K-E190K -COSY-UGT71E-S8H, pCS-TAL-FreHpaBC-COMT-4CL). In this embodiment, the quercetin synthesis engineering bacteria BW4 is equivalent to the strain BW40: BW30 (pZE-UGT71E).
[0140] (2) Synthesis of quercetin by adding ferulic acid in vitro
[0141] The above-mentioned qinpidin synthesis engineering bacteria BW40 constructed in this example was streaked and cultured on LB plate medium with corresponding resistance, and single colonies were picked from the corresponding plates and added to 4 mL of liquid LB medium with resistance, and cultured at 37°C for 16 hours, and then the bacterial liquid was transferred to 50 mL of fermentation medium, and 100 mg / L of ferulic acid was added to the fermentation medium, and 0.5 mM IPTG was added for induction. After that, samples were taken at 24, 48, and 72 hours, and the concentrations of the intermediates and target products were determined by high performance liquid chromatography. The results are as follows: Figure 6 Among them, the fraxin-8-O-glycosyltransferases in the fraxin-synthesizing engineered bacteria BW40 in this embodiment are UGT71E1, UGT71E2, and UGT71E3, respectively, and the corresponding strains are denoted as fraxin-synthesizing engineered bacteria BW41, BW42, and BW43, respectively.
[0142] from Figure 6 It can be seen that under the same conditions, by adding ferulic acid in vitro, the quercetin synthesis engineering bacteria BW41 with quercetin-8-O-glycosyltransferase UGT71E1 was fermented for 72 hours, and the production of quercetin reached 165.3 mg / L.
[0143] (3) De novo synthesis of quercetin using simple carbon sources
[0144] Using a simple carbon source as the source, the de novo synthesis of quercetin using the quercetin synthesis engineered bacteria BW41 is achieved. Compared with the synthesis of quercetin by adding ferulic acid in vitro, the main difference is that no additional ferulic acid is added to the fermentation medium used in the de novo synthesis of quercetin, and the other process methods are the same. Among them, the fermentation situation of the de novo synthesis of quercetin using the quercetin synthesis engineered bacteria BW41 is as follows Figure 7 As shown. Among them, Figure 7 Display: Utilizes feruloyl-CoA 6'-hydroxylase F6'H1 D102E-E163K-E190K The mutant quercetin-synthesizing engineered bacteria BW41 were fermented for 72 hours, and the de novo synthesis of quercetin production could reach 101.2 mg / L.
[0145] Example 6 Application of Feruloyl-CoA 6'-Hydroxylase F6'H1 Mutant in the Synthesis of Scopoletin
[0146] (1) Scopolamine synthesis engineering bacteria and construction method thereof
[0147] This embodiment provides a scopoletin synthesis engineering bacteria BW5: BW1 (pZE-F6'H1 D102E-E163K-E190K -COSY-GT, pCS-TAL-FreHpaBC-COMT-4CL).
[0148] The construction method of the scopoletin synthesis engineering bacteria is basically the same as the construction method of the engineering bacteria provided in Example 3. First, the recombinant plasmid pZE-F6'H1 is constructed. D102E-E163K-E190K -COSY-GT and pCS-TAL-FreHpaBC-COMT-4CL, among which, the recombinant plasmid pZE-F6'H1 D102E-E163K-E190K -COSY-GT mainly encodes F6'H1 D102E-E163K-E190K The genes of COSY and GT were connected to the same vector plasmid pZE12-luc to obtain the recombinant plasmid pZE-F6'H1 D102E -E163K-E190K -COSY-GT and pCS-TAL-FreHpaBC-COMT-4CL were electroporated into competent cells of Escherichia coli BW1 to construct scopoletin synthesis engineering bacteria BW5: BW1 (pZE-F6'H1 D102E-E163K-E190K -COSY-GT, pCS-TAL-FreHpaBC-COMT-4CL). In this embodiment, COSY is derived from Arabidopsis thaliana, that is, the scopoletin synthesis engineering bacteria BW5 in this embodiment is equivalent to BW50:BW23 (pZE-GT).
[0149] (2) Synthesis of scopoletin by adding ferulic acid in vitro
[0150] The scopoletin synthesis engineering bacteria BW50 constructed in this example were streaked and cultured on LB plate medium with corresponding resistance, and single colonies were picked from the corresponding plates and transferred to 4 mL of liquid LB medium with resistance, cultured at 37°C for 16 h, and then the bacterial liquid was transferred to 50 mL of fermentation medium, and 100 mg / L ferulic acid and 0.5 mM IPTG were added to the fermentation medium for induction. After that, samples were taken at 24, 48, and 72 hours, and the concentrations of the intermediates and target products were determined by high performance liquid chromatography. The results are as follows: Figure 8 As shown. Among them, the scopoletin-glycosyltransferase GT in this embodiment are TOGT1, TOGT2, UGT71E1, UGT71E2, and UGT71E3, and the corresponding strains are respectively represented as scopoletin synthesis mutant engineering bacteria BW50, BW51, BW52, BW53, and BW54.
[0151] from Figure 8 It can be seen that when ferulic acid is added in vitro, the scopolamine synthesis engineering bacteria BW50 with scopolamine-glycosyltransferase TOGT1 can achieve a scopolamine production of 94.6 mg / L after fermentation for 72 hours.
[0152] (3) De novo synthesis of scopolamine using simple carbon sources
[0153] Using a simple carbon source as the source, the de novo synthesis of scopolamine using the scopolamine synthesis engineered bacteria BW50 is achieved. Compared with the synthesis of scopolamine by adding ferulic acid in vitro, the main difference is that no ferulic acid is added to the fermentation medium used in the de novo synthesis of scopolamine, and the other process methods are the same. Among them, the fermentation situation of de novo synthesis of quercetin using the scopolamine synthesis engineered bacteria BW50 is shown in the figure. Fig. 9 As shown. Among them, Fig. 9 It is shown that: using feruloyl-CoA 6'-hydroxylase F6'H1 D102E-E163K-E190K The mutant scopolamine-synthesizing engineered bacteria BW50 were fermented for 72 hours, and the de novo scopolamine production could reach 79.8 mg / L.
[0154] Example 7 Application of Feruloyl-CoA 6'-Hydroxylase F6'H1 Mutant in the Synthesis of Fraxin
[0155] (1) Engineering bacteria for the synthesis of esculetin and methods for its construction
[0156] This embodiment provides a esculetin synthesis engineering bacterium BW6:BW1 (pZE-F6'H1-COSY, pCS-TAL-FreHpaBC-4CL).
[0157] The construction method of the engineering bacteria for synthesizing quinoline is basically the same as the construction method of the engineering bacteria provided in Example 3. First, recombinant plasmids pZE-F6'H1-COSY and pCS-TAL-FreHpaBC-4CL are constructed, wherein the recombinant plasmid pZE-F6'H1-COSY is mainly obtained by connecting the genes encoding F6'H1 and COSY to the same vector plasmid pZE12-luc; then, the recombinant plasmids pZE-F6'H1-COSY and pCS-TAL-FreHpaBC-4CL are electroporated into the competent cells of Escherichia coli BW1 to construct the engineering bacteria for synthesizing quinoline BW6:BW1 (pZE-F6'H1-COSY, pCS-TAL-FreHpaBC-4CL).
[0158] (2) De novo synthesis of esculetin using simple carbon sources
[0159] The aesculin synthesis engineering bacteria BW6 constructed in this example were streaked on LB plate medium with corresponding resistance, and single colonies were picked from the corresponding plates and added to 4 mL of liquid LB with resistance, cultured at 37°C for 16 h, and then the bacterial liquid was transferred to 50 mL of fermentation medium, and 0.5 mM IPTG was added for induction. Samples were taken at 24, 48, and 72 hours, and the concentrations of the intermediates and target products were determined by high performance liquid chromatography. The results are shown in Table 8 and Fig.10As shown. Among them, COSY in the aesculetin synthesis engineering bacteria BW6 comes from Arabidopsis thaliana, Solanum tuberosum, and Glycine max, and the corresponding strains are respectively represented as aesculetin synthesis engineering bacteria BW60, BW61, and BW62. The aesculetin synthesis engineering bacteria BW63 is basically the same as strain BW60, and the main difference is that: F6'H1 in strain BW64 is a mutant F6'H1 D102E-E163K-E190K , that is, strain BW64 is a mutant engineered bacterium for synthesizing aesculetin, represented by BW1(pZE-F6'H1 D102E-E163KE190K -COSY, pCS-TAL-FreHpaBC-4CL); F6'H1 in strain BW60 is wild type, that is, strain BW60 wild type aesculetin synthesis engineering bacteria; other enzymes and their sources are the same.
[0160] Table 8 Results of synthesizing aesculetin using aesculetin synthetic engineering bacteria for 72h fermentation
[0161] strain BW60 BW61 BW62 BW63 Yield / mg / L 15.5 13.2 10.8 78.4
[0162] From Table 8 and Fig.10 It can be seen that: using feruloyl-CoA 6'-hydroxylase F6'H1 D102E-E163K-E190K Among the mutant aestivin-synthesizing engineered bacteria, under the same conditions, the amount of aestivin produced by the aestivin-synthesizing engineered strain BW63 derived from Arabidopsis thaliana by COSY fermented for 72 hours reached 78.4 mg / L, which was about 5.1 times that of the wild type.
[0163] Example 8 Application of Feruloyl-CoA 6'-Hydroxylase F6'H1 Mutant in Synthesis of Aesculin
[0164] (1) Aesculin synthesis engineering bacteria and construction method thereof
[0165] This embodiment provides a kind of engineering bacteria BW7: BW1 (pZE-F6'H1 D102E-E163K-E190K -COSY-UGT, pCS-TAL-FreHpaBC-4CL).
[0166] The construction method of the aesculin synthesis engineering bacteria is basically the same as the construction method of the engineering bacteria provided in Example 3. First, the recombinant plasmid pZE-F6'H1 is constructed. D102E-E163K-E190K -COSY-UGT and pCS-TAL-FreHpaBC-4CL, among which, the recombinant plasmid pZE-F6'H1 D102E-E163K-E190K -COSY-UGT mainly encodes F6'H1 D102E-E163K-E190KThe genes of COSY and UGT were connected to the same vector plasmid pZE12-luc to obtain the recombinant plasmid pZE-F6'H1 D102E-E163K-E190K -COSY-UGT and pCS-TAL-FreHpaBC-4CL were electroporated into competent cells of Escherichia coli BW1 to construct the aesculin synthesis engineering bacteria BW7: BW1 (pZE-F6'H1 D102E-E163K-E190K -COSY-UGT, pCS-TAL-FreHpaBC-4CL). In this embodiment, COSY is derived from Arabidopsis thaliana, that is, the aesculin synthesis engineering bacteria BW7 in this embodiment is equivalent to BW70:BW63 (pZE-UGT).
[0167] (2) Synthesis of esculin by adding caffeic acid in vitro
[0168] The above-mentioned qinpixin synthetic engineering bacteria BW70 constructed in this example was streaked and cultured on a LB plate medium with corresponding resistance, and single colonies were picked from the corresponding plates and inoculated into 4 mL of liquid LB culture medium with resistance, and cultured at 37°C for 16 hours, and then the bacterial liquid was transferred to 50 mL of fermentation medium, and 100 mg / L of caffeic acid was added to the fermentation medium, and 0.5 mM IPTG was added for induction. After that, samples were taken at 24, 48, and 72 hours, and the concentrations of the intermediates and target products were determined by high performance liquid chromatography. The results are as follows: Fig.10 Among them, the aesculetin-6-O-glycosyltransferase UGTs in this embodiment are UGT92G7 and UGT84A62, and the corresponding strains are respectively denoted as aesculetin synthesis engineering bacteria BW71 and BW72.
[0169] from Fig.11 It can be seen that when caffeic acid is added in vitro, the esculin synthesis engineering bacteria BW71 using the esculin-6-O-glycosyltransferase UGT92G7 can achieve a esculin production of 120.1 mg / L after 72 hours of fermentation.
[0170] (3) De novo synthesis of fraxin using simple carbon sources
[0171] Using a simple carbon source as the source, the de novo synthesis of quercetin using the quercetin synthesis engineered bacteria BW71 is achieved. Compared with the synthesis of quercetin by adding caffeic acid in vitro, the main difference is that no additional caffeic acid is added to the fermentation medium used in the de novo synthesis of quercetin, and the other process methods are the same. Among them, the fermentation situation of de novo synthesis of quercetin using the quercetin synthesis engineered bacteria BW71 is shown in the figure. Fig.12 As shown. Among them, Fig.12 It is shown that: using feruloyl-CoA 6'-hydroxylase F6'H1D102E-E163K-E190K The mutant quinolin synthesis engineering bacteria BW71 was fermented for 72 hours, and the de novo synthesis quinolin production could reach 254.8 mg / L.
[0172] Example 9 Application of Feruloyl-CoA 6'-Hydroxylase F6'H1 Mutant in Synthesis of Chicorin
[0173] (1) Chicorylin synthesis engineering bacteria and construction method thereof
[0174] This embodiment provides a chicorylin synthesis engineering bacterium BW8: BW1 (pZE-F6'H1 D102E-E163K-E190K -COSY-GT, pCS-TAL-FreHpaBC-4CL).
[0175] The construction method of the chicorylin synthesis engineering bacteria is basically the same as the construction method of the engineering bacteria provided in Example 3. First, the recombinant plasmid pZE-F6'H1 is constructed. D102E-E163K-E190K -COSY-GT and pCS-TAL-FreHpaBC-4CL, among which, the recombinant plasmid pZE-F6'H1 D102E-E163K-E190K -COSY-GT mainly encodes F6'H1 D102E-E163K-E190K The genes of COSY and GT were connected to the same vector plasmid pZE12-luc to obtain the recombinant plasmid pZE-F6'H1 D102E-E163K-E190K -COSY-GT and pCS-TAL-FreHpaBC-4CL were electroporated into competent cells of Escherichia coli BW1 to construct chicorylin synthesis engineering bacteria BW8: BW1 (pZE-F6'H1 D102E-E163K-E190K -COSY-GT, pCS-TAL-FreHpaBC-4CL). In this embodiment, COSY is derived from Arabidopsis thaliana, that is, the chicorin synthesis engineering bacteria BW8 in this embodiment is equivalent to BW80:BW63 (pZE-GT).
[0176] (2) Synthesis of chicory glycoside by adding caffeic acid in vitro
[0177] The chicorin synthesis engineered bacteria BW80 constructed in this example were streaked and cultured on LB plate medium with corresponding resistance, and single colonies were picked from the corresponding plates and inoculated into 4 mL of liquid LB medium with resistance, and cultured at 37°C for 16 hours, and then the bacterial liquid was transferred to 50 mL of fermentation medium, and 100 mg / L of caffeic acid and 0.5 mM IPTG were added to the fermentation medium for induction. Afterwards, samples were taken at 24, 48, and 72 hours, and the concentrations of the intermediates and target products were determined by high performance liquid chromatography. The results are as follows: Fig.13As shown. In this embodiment, the scopoletin-glycosyltransferase GTs are TOGT1 and TOGT2, and the corresponding strains are chicorylin synthesis engineering bacteria BW81 and BW82, respectively.
[0178] from Fig.13 It can be seen that when caffeic acid is added in vitro, feruloyl-CoA 6'-hydroxylase F6'H1 D102E -E163K-E190K The scopoletin-glycosyltransferase in the mutant chicory glycoside synthesis engineering bacteria BW81 is TOGT1 derived from tobacco, and its fermentation for 72 hours can make the chicory glycoside production reach 88.6 mg / L.
[0179] (3) De novo synthesis of chicory glycosides using simple carbon sources
[0180] Using a simple carbon source as the source, chicorin synthesis engineered bacteria BW81 was used to synthesize chicorin from scratch. Compared with the synthesis of chicorin by adding caffeic acid in vitro, the main difference is that no caffeic acid was added to the fermentation medium used in the process of synthesizing chicorin from scratch, and the other process methods were the same. Among them, the fermentation situation of chicorin synthesized from scratch by chicorin synthesis engineered bacteria BW81 is shown in the figure. Fig.14 shown.
[0181] Fig.14 It is shown that: using feruloyl-CoA 6'-hydroxylase F6'H1 D102E-E163K-E190K The mutant chicory glycoside-synthesizing engineered bacteria BW81 were fermented for 72 hours, and the yield of chicory glycoside synthesized from scratch could reach 73.9 mg / L.
[0182] Therefore, the surface mutant of feruloyl-CoA 6'-hydroxylase provided in the embodiment of the present invention can improve the pathway efficiency without affecting the growth of the bacterial cell by improving the catalytic efficiency of the enzyme through directed evolution on the basis of the wild-type F6'H1. The engineering bacteria constructed by further using the feruloyl-CoA 6'-hydroxylase mutant provided in the embodiment of the present invention to produce coumarin compounds have the advantages of high yield and a wide variety, which is conducive to industrialized scale-up production and reduces production costs, and provides an important basis for the industrial production of coumarin compounds.
[0183] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, ordinary technicians in the field should understand that the specific implementation methods of the present invention can still be modified or some technical features can be replaced by equivalents without departing from the spirit of the technical solution of the present invention, which should be included in the scope of the technical solution for protection of the present invention.
Claims
1. A feruloyl-CoA 6'-hydroxylase mutant, characterized in that: Mainly obtained by amino acid mutation of the amino acid sequence shown in SEQ ID NO.1, including at least one of the following amino acid mutations: D102E, E163K, E190K, L196F, K199N; Preferably, the amino acid mutation is a double mutation, a triple mutation, a quadruple mutation or a penta mutation; More preferably, the amino acid mutation is D102E-E190K or D102E-E163K-E190K; Preferably, the feruloyl-CoA 6'-hydroxylase is derived from Arabidopsis thaliana A. thaliana .
2. A gene encoding the feruloyl-CoA 6'-hydroxylase mutant according to claim 1.
3. A recombinant plasmid, characterized in that: It is connected to the gene according to claim 2; Preferably, the recombinant plasmid comprises pETDuet-1, pZE12-luc, pCS27 or pSA74.
4. An engineered bacterium for synthesizing coumarin compounds, characterized in that: A host bacterium and the recombinant plasmid according to claim 3 transformed into the host bacterium; Preferably, the coumarin compound is aesculetin, aesculetin, chicory glycoside, scopoletin, aesculetin, aesculetin or scopolamine; Preferably, the host bacteria are original bacteria or fungi, or modified bacteria or fungi; More preferably, the host bacteria is Escherichia coli BW25113 or recombinant Escherichia coli BW25113ΔpykA / F::aroG fbr ::tyrA fbr .
5. The engineered bacteria according to claim 4, characterized in that: The recombinant plasmid is also connected with genes encoding tyrosine ammonia lyase, flavin reductase, p-hydroxyphenylacetic acid-3-hydroxylase, caffeic acid methoxytransferase, p-coumaroyl-CoA ligase and coumarin synthase; Preferably, the coumarin synthase is derived from Arabidopsis thaliana A. thaliana ,potato Solanum tuberosum or soybean Glycine max .
6. The engineered bacteria according to claim 5, characterized in that: The recombinant plasmid is also connected with a gene encoding scopoletin-glycosyltransferase; Preferably, the scopoletin-glycosyltransferase is derived from tobacco Nicotiana tabacum Arabidopsis thaliana Arabidopsis thaliana .
7. The engineered bacteria according to claim 5, characterized in that: The recombinant plasmid is also connected with a gene encoding scopoletin-8-hydroxylase; Preferably, the scopoletin-8-hydroxylase is derived from Arabidopsis thaliana Arabidopsis thaliana .
8. The engineered bacteria according to claim 7, characterized in that: The recombinant plasmid is also connected to a gene encoding fraxin-8-O-glycosyltransferase; Preferably, the fraxin-8-O-glycosyltransferase is derived from Arabidopsis thaliana Arabidopsis thaliana .
9. The engineered bacteria according to claim 4, characterized in that: The recombinant plasmid is also connected with genes encoding tyrosine ammonia lyase, flavin reductase, p-hydroxyphenylacetic acid-3-hydroxylase, p-coumaroyl-CoA ligase and coumarin synthetase; Preferably, the coumarin synthase is derived from Arabidopsis thaliana A. thaliana ,potato Solanum tuberosum or soybean Glycine max .
10. The engineered bacteria according to claim 9, characterized in that: The recombinant plasmid is also connected with a gene encoding scopoletin-glycosyltransferase; Preferably, the scopoletin-glycosyltransferase is derived from tobacco Nicotiana tabacum Arabidopsis thaliana Arabidopsis thaliana .
11. The engineered bacteria according to claim 9, characterized in that: The recombinant plasmid is also connected to a gene encoding aesculetin-6-O-glycosyltransferase; Preferably, the aesculetin-6-O-glycosyltransferase is derived from Acer truncatum Dipteronia sinensis .
12. A method for biosynthesis of coumarin compounds, comprising: The step of inoculating the engineered bacteria according to any one of claims 4 to 11 into a fermentation medium at an inoculation volume fraction of 1% to 10% for fermentation culture to obtain coumarin compounds; Preferably, the inoculation amount is 2% to 5%, and the fermentation temperature is 30°C to 40°C; Preferably, the fermentation medium comprises: 0.5-1.5 g / L FeSO4, 1-5 g / L MOPS, 5-20 g / L carbon source, 1-5 g / L yeast powder, 5-8 g / L Na2HPO4, 0.3-2 g / L NaCl, 2.3-4.0 g / L KH2PO4 and 1-5 g / L NH4Cl.
13. The synthesis method according to claim 12, characterized in that: The step also includes first adding an intermediate compound to the fermentation medium, and then fermenting and culturing the engineered bacteria; Preferably, the intermediate compound is at least one of tyrosine, p-coumaric acid, caffeic acid, ferulic acid, scopoletin, fraxinusin and fraxinetin.
Citation Information
Patent Citations
Method for heterologous biosynthesis of tonquinol, caffeol and ferulenol
CN105907804A
Recombinant yeast capable of producing caffeic acid and / or ferulic acid
US20220372431A1
